PTIXW
Protagenic Therapeutics, Inc. [PTIXW] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PTIXW Stock Summary
In the News
PTIXW Financial details
Company Rating
-
Market Cap
7.23M
Income
-5.01M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
1
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-0.95
Forward P/E
-
PEG
-0.25
P/S
-
P/B
0.9
P/C
-
P/FCF
-1.39
Quick Ratio
4.12
Current Ratio
4.2
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.15
EPS next Y
-
EPS next Q
-
EPS this Y
38.55%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
18.75%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-73%
ROE
-69%
ROC
-0.96%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.027-0.027
52W High
-
52W Low
-
RSI
54
Rel Volume
-
Avg Volume
-
Volume
6K
Perf Week
-10%
Perf Month
170%
Perf Quarter
-
Perf Half Y
-3.57%
-
-
-
-
Beta
0.383
-
-
Volatility
0%, 0.01%
Prev Close
0%
Price
0.027
Change
0%
Company Profile
- Market Capitalization 7.23M
- Employee 1
- CEO Dr. Garo H. Armen Ph.D.
- Headquarters New York,NY,US
- IPO Date 2021-04-27
-
Website
http://www.protagenic.com 
Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.
